Abstract:Approximately 20% of head and neck squamous cell carcinomas (HNSCCs) exhibit reduced methylation on lysine 36 of histone H3 (H3K36me) due to mutations in histone methylase NSD1 or a lysine-to-methionine mutation in histone H3 (H3K36M). Whether such alterations of H3K36me can be exploited for therapeutic interventions is still unknown. Here, we show that HNSCC models expressing H3K36M can be divided into two groups: those that display aberrant accumulation of H3K27me3 and those that maintain steady levels of H3K27me3. The former group exhibits reduced proliferation, genome instability, and heightened sensitivity to genotoxic agents like PARP1/2 inhibitors. Conversely, H3K36M HNSCC models with constant H3K27me3 levels lack these characteristics unless H3K27me3 is elevated by DNA hypomethylating agents or inhibiting H3K27me3 demethylases KDM6A/B. Mechanistically, H3K36M reduces H3K36me by directly impeding the activities of the histone methyltransferase NSD3 and the histone demethylase LSD2. Notably, aberrant H3K27me3 levels induced by H3K36M expression are not a bona fide epigenetic mark because they require continuous expression of H3K36M to be inherited. Moreover, increased sensitivity to PARP1/2 inhibitors in H3K36M HNSCC models depends solely on elevated H3K27me3 levels and diminishing BRCA1- and FANCD2-dependent DNA repair. Finally, a PARP1/2 inhibitor alone reduces tumor burden in a H3K36M HNSCC xenograft model with elevated H3K27me3, whereas in a model with consistent H3K27me3, a combination of PARP1/2 inhibitors and agents that up-regulate H3K27me3 proves to be successful. These findings underscore the crucial balance between H3K36 and H3K27 methylation in maintaining genome instability, offering new therapeutic options for patients with H3K36me-deficient tumors.

Histone Lysine-to-Methionine Mutation As Anticancer Drug Target

Histone Demethylase Lysine Demethylase 5B in Development and Cancer

Recent Advances in Targeting Histone H3 Lysine 36 Methyltransferases for Cancer Therapy

Histone Lysine Methylation and Cancer

Histone lysine methyltransferases as anti-cancer targets for drug discovery

Prominent Role of Histone Lysine Demethylases in Cancer Epigenetics and Therapy

Histone Methyltransferases: Novel Targets for Tumor and Developmental Defects.

The modification role and tumor association with a methyltransferase: KMT2C

Novel Insights into Histone Lysine Methyltransferases in Cancer Therapy: from Epigenetic Regulation to Selective Drugs

Histone Mutations and Cancer

Molecular Mechanisms of Epigenetic Regulators As Activatable Targets in Cancer Theranostics.

The Roles of Histone Modifications in Tumorigenesis and Associated Inhibitors in Cancer Therapy.

Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors

Role of Several Histone Lysine Methyltransferases in Tumor Development

Mechanism of Cancer: Oncohistones in Action

The role of histone post-translational modifications in cancer and cancer immunity: functions, mechanisms and therapeutic implications

Lysine Methylation of Transcription Factors in Cancer

Histone methyltransferase and drug resistance in cancers

Small Molecules Targeting the Specific Domains of Histone-Mark Readers in Cancer Therapy

Methylation of histone H3 lysine 36 is a barrier for therapeutic interventions of head and neck squamous cell carcinoma

Writing, erasing and reading histone lysine methylations